Introduction:
Liraglutide, a glucagon-like peptide 1 receptor agonist (GLP-1) utilized
for management of type 2 diabetes mellitus, has been associated with
reduced risk of cardiovascular events. However, it is also associated
with increased heart rate and reduced heart rate variability. In this
study, we investigate the effect of liraglutide in patients with atrial
fibrillation (AF).